'Ovarian cryopreservation versus ovarian suppression by GnRH analogues: Primum non nocere': Reply [5]

Human Reproduction

Volumn 19, Issue 7, 2004, Pages 1681-1683

  Oktay, Kutluk ^a   Sonmezer, Murat ^b   Oktem, Ozgur ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; FOLLITROPIN RECEPTOR; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADOTROPIN; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CRYOPRESERVATION; FEMALE; GONADAL DISEASE; GRANULOSA CELL; HUMAN; IN SITU HYBRIDIZATION; LETTER; LYMPHOMA; MENARCHE; NONHUMAN; OOCYTE; OVARY CANCER; OVARY FOLLICLE CELL; OVARY FUNCTION; OVARY INSUFFICIENCY; PATIENT COUNSELING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 3242892684     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (23)

1. Atya K, Rao LV, Lawrence E and Kimmel R (1995) Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 52,365-372.
2. Beauchamp TL and Childress JF (1994) Principles of Biomedical Ethics, 4th edn. Oxford University Press, New York, p. 11.
3. Blumenfeld Z (2004) Ovarian cryopreservation versus ovarian suppression by GnRH analogues: primum non nocere. Hum Reprod 19,
4. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M and Haim N (1996) Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 11,1620-1626.
5. Emons G, Grundker C, Gunthert AR, Westphalen S, Kavanagh J and Verschraegen C. (2003) GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer 10,291-299.
6. Flaws JA, Abbud R, Mann RJ, Nilson JH and Hirshfield AN (1997) Chronically elevated luteinizing hormone depletes primordial follicles in the mouse ovary. Biol Reprod 57,1233-1237.
7. Gamcsik MP, Dolan ME, Andersson BS and Murray D (1999) Mechanisms of resistance to the toxicity of cyclophosphamide. Curr Pharm Des 5,587-605.
8. Johnson J, Canning J, Kaneko T, Pru JK and Tilly JL (2004) Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 428,145-150.
9. Meduri G, Touraine P, Beau I, Lahuna O, Desroches A, Vacher-Lavenu MC, Kuttenn F and Misrahi M (2003) Delayed puberty and primary amenorrhea associated with a novel mutation of the human follicle-stimulating hormone receptor: clinical, histological, and molecular studies. J Clin Endocrinol Metab 88,3491-3498.
10. Meirow D, Lewis H, Nugent D and Epstein M (1999) Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod 14,1903-1907.
11. 1 phase of the cell cycle. Br J Cancer 63,930-932.
12. Oktay K, Briggs D and Gosden RG (1997) Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab 82,3748-3751.
13. Oktay K, Newton H, Mullan J and Gosden RG (1998) Development of human primordial follicles to antral stages in SCID/hpg mice stimulated with follicle stimulating hormone. Hum Reprod 13,1133-1138.
14. Patsoula E, Loutradis D, Drakakis P, Michalas L, Bletsa R and Michalas S (2003) Messenger RNA expression for the follicle-stimulating hormone receptor and luteinizing hormone receptor in human oocytes and preimplantation-stage embryos. Fertil Steril 79,1187-1193.
15. Pereyra Pacheco B, Mendez Ribas JM, Milone G, Fernandez I, Kvicala R, Mila T, Di Noto A, Contreras Ortiz O and Pavlovsky S (2001) Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 81,391-397.
16. Rahilly M, Carder PJ, al Nafussi A and Harrison DJ (1991) Distribution of glutathione S-transferase isoenzymes in human ovary. J Reprod Fertil 93,303-311.
17. Revel A and Schenker J (2004) Ovarian tissue banking for cancer patients: is ovarian cortex cryopreservation presently justified? Hum Reprod 19,14-19
18. Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E and Bougneres PF (1998) Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 22,989-994.
19. Toft E, Becedas L, Soderstrom M, Lundqvist A and Depierre JW (1997) Glutathione transferase isoenzyme patterns in the rat ovary. Chem-Biol Interact 108,79-93.
20. Volker P, Grundker C, Schmidt O, Schulz KD and Emons G (2002) Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 186,171-179.
21. Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S, Crowther D, Rees LH, Besser GM, Malpas JS et al. (1987) Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 19,159-162.
22. Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D and Beardwell C (1983) The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer 52,988-993.
23. Zheng W, Magid MS, Kramer EE and Chen YT (1996) Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol 148,47-53.